Agree - hence our conclusion in editorial that these data can't tell us that much. We've been thinking about how to actually solve this problem - see www.clinicalmicrobiologyandinfection.com/article/S119... Possibly using an ACORN type approach to facilitate the trial design

Thanks, will have a look An ACORN style approach sounds like a very good idea, though not sure I'd want to be randomised to an arm that didn't receive a beta lactam The beauty of linezolid is that you can use ceftriaxone upfront, without worrying about MRSA Factorial randomisation to IVIG vs not?